ADOCIA Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to
- Number of shares : 10,329
- Cash balance of the liquidity account: € 208,460.92
During the 1st half of 2024, a total of:
Buy side |
158,186 shares |
€ 1,462,708.28 |
928 transactions |
Sell side |
150,404 shares |
€ 1,421,855.74 |
935 transactions |
The following resources appeared on the last half year statement on
- Number of shares : 2,547
- Cash balance of the liquidity account: € 245,713.33
The following resources appeared on the liquidity account when the activity started:
- Number of shares : 15,026
- Cash balance of the liquidity account: € 300,000.00
The liquidity agreement complies with AMF Decision n° 2021-01 of
About
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
The forward-looking statements contained in this press release are also subject to risks not yet known to
View source version on businesswire.com: https://www.businesswire.com/news/home/20240719170092/en/
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: